Quanta Therapeutics announced advancements in its KRAS-directed drug candidates, including FDA IND clearance for QTX3544, a G12V-preferring multi-KRAS inhibitor, allowing for a Phase 1 clinical trial. The company also initiated the combination phase of its ongoing Phase 1 trial evaluating QTX3046, a G12D-selective KRAS inhibitor, with cetuximab, an EGFR inhibitor. A separate Phase 1 trial evaluating QTX3034, a G12D-preferring multi-KRAS inhibitor, continues, with data anticipated in 2025.
These advancements are important because they expand the potential treatment options for patients with KRAS-driven cancers, specifically targeting the G12V, G12D, and G12C mutations prevalent in cancers like colorectal, pancreatic, and lung. The combination therapy approach with cetuximab aims to enhance treatment efficacy and durability, mirroring the successful strategy seen with adagrasib in KRAS G12C-mutated colorectal cancer. This progress suggests a broader reach toward addressing the high unmet need in treating these aggressive cancers.
QTX3034 and QTX3046 are distinct, oral, allosteric inhibitors targeting KRAS G12D mutations. QTX3544 is an oral multi-KRAS inhibitor with G12V-preferring activity. The Phase 1 trials are evaluating these candidates as monotherapies and in combination with cetuximab, focusing on safety, dosage, pharmacokinetics, and antitumor activity. These trials are ongoing in the U.S.
Quanta’s progress signals a potential shift in the landscape of KRAS-targeted therapies. The simultaneous development of multiple KRAS inhibitors, each with different mutation specificities and tested in combination with other targeted agents, could offer a personalized approach to cancer treatment. This could ultimately lead to improved outcomes for patients with various KRAS-driven cancers. The anticipated data readouts in 2025 will be crucial in determining the clinical viability of these promising candidates and further shaping the future direction of KRAS-focused drug development.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
